Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 28:16:5.
doi: 10.1186/s40360-015-0005-1.

Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome

Masahiro Inoue  1   2 , Manabu Shoji  3   4 , Naomi Shindo  5 , Kazunori Otsuka  6   7 , Masatomo Miura  8 , Hiroyuki Shibata  9   10
Affiliations

Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome

Masahiro Inoue et al. BMC Pharmacol Toxicol. .

Abstract

Background: Chemotherapy-induced nausea and vomiting is one of the most influential factors that affect patient quality of life; thus, preventing this adverse event could lead to better patient outcome. Standard preventive guidelines for antiemetic treatment have already been established based on the emetogenicity of chemotherapeutic agents. It is important that compliance with in-house guidelines and their effect on patient outcome is monitored.

Methods: In 3 years since the Akita university hospital antiemetic guidelines were outlined, we assessed the incidence of chemotherapy-induced nausea and vomiting using the antiemesis tool of the Multinational Association of Supportive Care in Cancer. Compliance of the guidelines was extracted from the hospital clinical record, and the chemotherapy-induced nausea and vomiting was examined by the patient reported outcome.

Results: Seventy-three patients answered the questionnaire. The overall compliance rate with the guidelines for early nausea and vomiting was 98.6% and with the delayed nausea and vomiting was 87.7%. The complete response rate for the early and delayed chemotherapy-induced nausea and vomiting was 77.8% and 73.8%, respectively. The overall relative risk of early nausea and vomiting was 0.22 (P < 0.05), whereas the relative risk for delayed nausea and vomiting was 2.09 (P < 0.05). Breakthrough vomiting was observed in 3 cases in the low-risk group only. These data suggest that delayed nausea and vomiting is difficult to prevent, particularly in the low-risk group. Further, it seems that the individual sensitivity for emetogenicity might differ among patients.

Conclusions: In addition to standard prevention guidelines based on emetogenicity, individual care based on patient reports should be considered for the complete prevention of chemotherapy-induced nausea and vomiting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic presentation of this study. Comparison between compliance of anti-emetic guideline and patient reported outcome.
Figure 2
Figure 2
Patient-reported outcome regarding early CINV in patients treated with sufficient antiemetic guidelines. Mini, minimal-risk group; mod, moderate-risk group. An open circle indicates the case with a complete response. The shaded circle indicates CIN (the number corresponds to the grade of nausea). The closed rectangle indicates CIV (the number corresponds to the number of times of vomiting).
Figure 3
Figure 3
Patient-reported outcome regarding delayed CINV in patients treated with sufficient antiemetic guidelines. Mini, minimal-risk group; mod, moderate-risk group. An open circle indicates the case with a complete response. The shaded circle indicates CIN (the number corresponds to the grade of nausea). The closed rectangle indicates CIV (the number corresponds to the number of times of vomiting).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. Br Med J. 1979;1:1323–4. doi: 10.1136/bmj.1.6174.1323-a. - DOI - PMC - PubMed
    1. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol. 1988;6:1746–52. - PubMed
    1. Baker PD, Morzorati SL, Ellett ML. The pathophysiology of chemotherapy-induced nausea and vomiting. Gastroenterol Nurs. 2005;28:469–80. doi: 10.1097/00001610-200511000-00003. - DOI - PubMed
    1. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932–47. doi: 10.1200/JCO.2006.06.9591. - DOI - PubMed
    1. Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21:1083–8. doi: 10.1093/annonc/mdp584. - DOI - PubMed

Substances